Structure of HIV-1 quasi-species as early indicator for switches of co-receptor tropism
© Dybowski et al; licensee BioMed Central Ltd. 2010
Received: 22 September 2010
Accepted: 30 November 2010
Published: 30 November 2010
Deep sequencing is able to generate a complete picture of the retroviral quasi-species in a patient. We demonstrate that the unprecedented power of deep sequencing in conjunction with computational data analysis has great potential for clinical diagnostics and basic research. Specifically, we analyzed longitudinal deep sequencing data from patients in a study with Vicriviroc, a drug that blocks the HIV-1 co-receptor CCR5. Sequences covered the V3-loop of gp120, known to be the main determinant of co-receptor tropism. First, we evaluated this data with a computational model for the interpretation of V3-sequences with respect to tropism, and we found complete agreement with results from phenotypic assays. Thus, the method could be applied in cases where phenotypic assays fail. Second, computational analysis led to the discovery of a characteristic pattern in the quasi-species that foreshadows switches of co-receptor tropism. This analysis could help to unravel the mechanism of tropism switches, and to predict these switches weeks to months before they can be detected by a phenotypic assay.
Human Immunodeficiency Virus 1 (HIV-1) enters cells in a complex process involving interactions of viral envelope protein gp120 with the cellular receptor CD4 and a co-receptor, typically one of the chemokine receptors CCR5 or CXCR4 . According to their co-receptor usage or "tropism", viruses are classified as "R5" (interacting with CCR5) or "X4" (interacting with CXCR4). Additionally, there are dual-tropic "R5X4" strains that use both co-receptors for cell entry. Tropism is mainly determined by the sequence of the variable loop 3 (V3) of gp120. In initial infection, R5 viruses dominate the viral quasi-species . As the disease progresses, about 50% of the patients develop X4 virus . CCR5 blocking drugs, such as Maraviroc or Vicriviroc [4, 5] are ineffective against X4 virus, and thus it is advisable to test tropism prior to treatment with these drugs. The current state-of-the-art is testing by phenotypic assays such as Trofile® (Monogram Biosciences, CA)  or enhanced sensitivity Trofile® assay (ESTA) . However, their restriction to specialized laboratories, high cost and long turn-around are limiting availability. Moreover, phenotypic assays have been reported to fail in delivering any result in more than 15% of the cases . An alternative for routine diagnostics is genotypic testing: the genomic sequence of V3 from a patient is interpreted using computational models that relate V3 sequence and tropism. These models are typically derived by machine learning methods from a training set of V3 sequences and corresponding phenotypic test results [9–14]. Genotypic predictions can be made available via the Internet, and they are fast and cheap. Failure rates have been estimated to be around 7.5% . In clinical settings with tropism predictions based on single sequences from bulk sequencing, genotypic methods tend to perform less well , which is mostly attributed to low detection rates of X4 minorities by bulk sequencing . Genotypic testing based on so-called "next generation sequencing" or "deep sequencing" methods may not suffer from this limitation  as they provide detailed data for the whole viral quasi-species. In fact, Vandenbroucke et al. have demonstrated that a combination of deep sequencing of V3 with a genotype interpretation algorithm [11, 19] can be used for determination of tropism even in cases where phenotypic testing fails. In their study, the error rate of prediction methods was a limiting factor.
Unique V3 sequences
We next exploited the property of T-CUP to provide in the first level two independent tropism predictions based on physical properties (electrostatics and hydropathy) of V3. The corresponding probabilities span a plane ("probabilities plane") in which every V3 sequence is represented by a point and the quasi-species by a cloud of such points. Figure 2 shows this plane for all twelve datasets from Ref.  with the points colored according to frequency of the respective sequence in the deep sequencing data.
The dynamics of the quasi-species in the probabilities plane has several remarkable features. First, all sequences in week 0 cluster in the lower left corner of the plane as is expected for a quasi-species that is R5 tropic. Second, the movement of the clouds indicates the dynamics of tropism. For Subjects 07 and 18 the clouds move towards the upper right, i.e. to more X4 tropism. For Subject 19 this movement is also seen for the first two time points but then reverts again to the lower left, i.e. to more R5 tropism. Subject 47 shows no marked movement to the upper right but remains localized in the lower left, in agreement with a quasi-species that remains R5 tropic. Third, for the patients 07, 18, and 19 where a co-receptor switch had been observed, there is only one clearly dominating X4 strain in the probabilities plane, and this strain is already present at therapy start with considerable frequency (bright spots with green arrows). This "X4 seed strain" is specific for each of the patients - the seed strains for different patients are clearly located in different regions of the probabilities plane. Additionally, the X4 seed strain is accompanied from the beginning by a growing halo of local minor variants. Note that Subject 47 who remains R5 tropic throughout all time points does not have such a cluster.
Development of X4 variants causing tropism switch
Fraction of population at
Although the high cost of deep sequencing will probably prevent its use in routine diagnostics in the near future, the combination of this powerful method with accurate predictions could be applied when phenotype testing fails and to study evolution of viral quasi-species under selective pressure, and thus contribute to the development of sustainably effective treatments.
This work was funded by BMBF grant 01ES0709 and DFG TRR 60/A6. The authors thank Hauke Walter for fruitful discussions, and Tsibris et al. for making their data available to the public.
- D'Souza MP, Harden VA: Chemokines and HIV-1 second receptors. Confluence of two fields generates optimism in AIDS research. Nat Med. 1996, 2 (12): 1293-1300. 10.1038/nm1296-1293View ArticlePubMedGoogle Scholar
- Connor RI, Sheridan KE, Ceradini D, Choe S, Landau NR: Change in coreceptor use correlates with disease progression in HIV-1-infected individuals. J Exp Med. 1997, 185 (4): 621-628. 10.1084/jem.185.4.621PubMed CentralView ArticlePubMedGoogle Scholar
- Berger EA, Murphy PM, Farber JM: Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease. Annu Rev Immunol. 1999, 17: 657-700. 10.1146/annurev.immunol.17.1.657View ArticlePubMedGoogle Scholar
- Dorr P, Westby M, Dobbs S, Griffin P, Irvine B, Macartney M, Mori J, Rickett G, Smith-Burchnell C, Napier C, Webster R, Armour D, Price D, Stammen B, Wood A, Perros M: Maraviroc (UK-427, 857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity. Antimicrob Agents Chemother. 2005, 49 (11): 4721-4732. 10.1128/AAC.49.11.4721-4732.2005PubMed CentralView ArticlePubMedGoogle Scholar
- Strizki JM, Tremblay C, Xu S, Wojcik L, Wagner N, Gonsiorek W, Hipkin RW, Chou CC, Pugliese-Sivo C, Xiao Y, Tagat JR, Cox K, Priestley T, Sorota S, Huang W, Hirsch M, Reyes GR, Baroudy BM: Discovery and characterization of vicriviroc (SCH 417690), a CCR5 antagonist with potent activity against human immunodeficiency virus type 1. Antimicrob Agents Chemother. 2005, 49 (12): 4911-4919. 10.1128/AAC.49.12.4911-4919.2005PubMed CentralView ArticlePubMedGoogle Scholar
- Whitcomb JM, Huang W, Fransen S, Limoli K, Toma J, Wrin T, Chappey C, Kiss LDB, Paxinos EE, Petropoulos CJ: Development and characterization of a novel single-cycle recombinant-virus assay to determine human immunodeficiency virus type 1 coreceptor tropism. Antimicrob Agents Chemother. 2007, 51 (2): 566-575. 10.1128/AAC.00853-06PubMed CentralView ArticlePubMedGoogle Scholar
- Saag M, Heera J, Goodrich J, DeJesus E, Clumeck N, Cooper D, Walmsley S, Ting N, Coakley E, Reeves J, Westby M, van der Ryst E, Mayer H: Reanalysis of the MERIT study with the enhanced Trofile assay (MERIT-ES). 48th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC. 2008,Google Scholar
- Poveda E, Seclen E, del Mar González M, García F, Chueca N, Aguilera A, Rodríguez JJ, Gonzalez-Lahoz J, Soriano V: Design and validation of new genotypic tools for easy and reliable estimation of HIV tropism before using CCR5 antagonists. J Antimicrob Chemother. 2009, 63 (5): 1006-1010. 10.1093/jac/dkp063View ArticlePubMedGoogle Scholar
- Resch W, Hoffman N, Swanstrom R: Improved success of phenotype prediction of the human immunodeficiency virus type 1 from envelope variable loop 3 sequence using neural networks. Virology. 2001, 288: 51-62. 10.1006/viro.2001.1087View ArticlePubMedGoogle Scholar
- Pillai S, Good B, Richman D, Corbeil J: A new perspective on V3 phenotype prediction. AIDS Res Hum Retroviruses. 2003, 19 (2): 145-149. 10.1089/088922203762688658View ArticlePubMedGoogle Scholar
- Jensen MA, Li FS, van't Wout AB, Nickle DC, Shriner D, He HX, McLaughlin S, Shankarappa R, Margolick JB, Mullins JI: Improved coreceptor usage prediction and genotypic monitoring of R5-to-X4 transition by motif analysis of human immunodeficiency virus type 1 env V3 loop sequences. J Virol. 2003, 77 (24): 13376-13388. 10.1128/JVI.77.24.13376-13388.2003PubMed CentralView ArticlePubMedGoogle Scholar
- Sander O, Sing T, Sommer I, Low AJ, Cheung PK, Harrigan PR, Lengauer T, Domingues FS: Structural descriptors of gp120 V3 loop for the prediction of HIV-1 coreceptor usage. PLoS Comput Biol. 2007, 3 (3): e58- 10.1371/journal.pcbi.0030058PubMed CentralView ArticlePubMedGoogle Scholar
- Xu S, Huang X, Xu H, Zhang C: Improved prediction of coreceptor usage and phenotype of HIV-1 based on combined features of V3 loop sequence using random forest. J Microbiol. 2007, 45 (5): 441-446.PubMedGoogle Scholar
- Dybowski JN, Heider D, Hoffmann D: Prediction of Co-Receptor Usage of HIV-1 from Genotype. PLoS Computational Biology. 2010, 6 (4): e1000743- 10.1371/journal.pcbi.1000743PubMed CentralView ArticlePubMedGoogle Scholar
- Low A, Dong W, Chan D, Sing T, Swanstrom R, Jensen M, Pillai S, Good B, Harrigan P: Current V3 genotyping algorithms are inadequate for predicting X4 co-receptor usage in clinical isolates. Aids. 2007, 21 (14): F17- 10.1097/QAD.0b013e3282ef81eaView ArticlePubMedGoogle Scholar
- Skrabal K, Low AJ, Dong W, Sing T, Cheung PK, Mammano F, Harrigan PR: Determining human immunodeficiency virus coreceptor use in a clinical setting: degree of correlation between two phenotypic assays and a bioinformatic model. J Clin Microbiol. 2007, 45 (2): 279-284. 10.1128/JCM.01118-06PubMed CentralView ArticlePubMedGoogle Scholar
- Swenson L, Dong W, Mo T, Woods C, Thielen A, Jensen M, Glascock C, Montaner J, Harrigan R: Quantification of HIV tropism by "deep" sequencing shows a broad distribution of prevalence of X4 variants in clinical samples that is associated with virological outcome. 16th Conference on Retroviruses and Opportunistic Infections, Montreal, Canada. 2009, 680- :Poster,Google Scholar
- Vandenbroucke I, Marck HV, Mostmans W, Eygen VV, Rondelez E, Thys K, Baelen KV, Fransen K, Vaira D, Kabeya K, Wit SD, Florence E, Moutschen M, Vandekerckhove L, Verhofstede C, Stuyver LJ: HIV-1 V3 envelope deep sequencing for clinical plasma specimens failing in phenotypic tropism assays. AIDS Research and Therapy. 2010, 7: 4- 10.1186/1742-6405-7-4PubMed CentralView ArticlePubMedGoogle Scholar
- Sing T, Low AJ, Beerenwinkel N, Sander O, Cheung PK, Domingues FS, Büch J, Däumer M, Kaiser R, Lengauer T, Harrigan PR: Predicting HIV coreceptor usage on the basis of genetic and clinical covariates. Antivir Ther. 2007, 12 (7): 1097-1106.PubMedGoogle Scholar
- Kyte J, Doolittle R: A simple method for displaying the hydropathic character of a protein. J Mol Biol. 1982, 157: 105-132. 10.1016/0022-2836(82)90515-0View ArticlePubMedGoogle Scholar
- Tsibris AMN, Korber B, Arnaout R, Russ C, Lo CC, Leitner T, Gaschen B, Theiler J, Paredes R, Su Z, Hughes MD, Gulick RM, Greaves W, Coakley E, Flexner C, Nusbaum C, Kuritzkes DR: Quantitative deep sequencing reveals dynamic HIV-1 escape and large population shifts during CCR5 antagonist therapy in vivo. PLoS One. 2009, 4 (5): e5683- 10.1371/journal.pone.0005683PubMed CentralView ArticlePubMedGoogle Scholar
- Smith TF, Waterman MS: Identification of common molecular subsequences. J Mol Biol. 1981, 147: 195-197. 10.1016/0022-2836(81)90087-5View ArticlePubMedGoogle Scholar
- Needleman S, Wunsch C: A general method applicable to the search for similarities in the amino acid sequence of two proteins. Journal of molecular biology. 1970, 48 (3): 443-453. 10.1016/0022-2836(70)90057-4View ArticlePubMedGoogle Scholar
- Heniko S, Heniko J: Amino acid substitution matrices from protein blocks. Proceedings of the National Academy of Sciences of the United States of America. 1992, 89 (22): 10915- 10.1073/pnas.89.22.10915View ArticleGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<url>http://creativecommons.org/licenses/by/2.0</url>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.